News
on
|
Research Feature
This article is the third in a three-part series about the NHLBI CADET II program. Although a variety of treatment options are available for patients with lung diseases such as asthma and chronic obstructive pulmonary disease (COPD), some patients do not respond to existing medications or experience side effects that limit the patients’ ability to...
|
News Release
A drug that blocks the action of a key hormone did not significantly improve a set of cardiovascular outcomes for patients with diastolic heart failure, a condition in which the heart is stiffer than normal and has problems filling with blood, according to a study supported by the National Institutes of Health. In terms of the study’s primary aim,...
|
News Release
WHAT: A long-term study of children with a complex heart condition called hypertrophic cardiomyopathy (HCM) found that the risk of death or need for immediate listing for heart transplantation was greatest for those who developed this disease as infants with congestive heart failure and for children who also had selective inborn errors of metabolis...
|
News Release
Administering to patients stem cells derived from their own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial supported by the National Institutes of Health. The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME...
|
Media Availability
WHAT: A protein known as galectin-3 can identify people at higher risk of heart failure, according to new research supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. This research is based on work from the NHLBI's Framingham Heart Study, which began in 1948 and has been the leading source...
|
News Release
Stem cells obtained from bone marrow, known as BMCs, can be safely injected into people 2-3 weeks following a heart attack, reports a new clinical trial supported by the National, Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. However, while safe, the BMCs did not improve heart function six months after their a...